Biologics Research Review, Issue 13

In this issue:

Adalimumab and infliximab for JIA-associated uveitis
Tocilizumab with or without methotrexate in RA
Belimumab in hypocomplementemic SLE
Tocilizumab discontinuation after remission in RA
Malignancy and mortality after TNF inhibitors for PsA
Subcutaneous vs intravenous ustekinumab induction for CD
Post-operative surgical site infection rates after vedolizumab
Vedolizumab for IBD
Concomitant 5-aminosalicylates in UC biologic therapy
Golimumab in clinical practice for moderately active UC
Long-term adalimumab in CD after loss of response to infliximab
Selective IL-23 inhibition by risankizumab in CD
5 years of secukinumab for moderate-to-severe psoriasis

Please login below to download this issue (PDF)

Subscribe